Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nelson L Michael

Showing results (351-360 of 372) with videos related to

Pageof 38
Sort By:
Cell Reports|August 10, 2023
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopesRajeshwer S Sankhala, Vincent Dussupt, Gina Donofrio, et al.
The Lancet. Infectious Diseases|January 29, 2022
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre studySaranya Sridhar, Arnel Joaquin, Matthew I Bonaparte, et al.
Plos Pathogens|August 4, 2015
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesSampa Santra, Georgia D Tomaras, Ranjit Warrier, et al.
The New England Journal of Medicine|April 2, 2015
A Recombinant Vesicular Stomatitis Virus Ebola VaccineJason A Regules, John H Beigel, Kristopher M Paolino, et al.
Structure (London, England : 1993)|December 29, 2023
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domainRajeshwer S Sankhala, Vincent Dussupt, Wei-Hung Chen, et al.
Plos One|November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Vaccines|May 28, 2022
A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) ModelSara C Johnston, Keersten M Ricks, Ines Lakhal-Naouar, et al.
JCI Insight|December 13, 2016
Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaquesKan Luo, Hua-Xin Liao, Ruijun Zhang, et al.
Nature Immunology|October 30, 2021
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinationsVincent Dussupt, Rajeshwer S Sankhala, Letzibeth Mendez-Rivera, et al.
Lancet (London, England)|July 27, 2018
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H Barouch, Frank L Tomaka, Frank Wegmann, et al.
Pageof 38

Showing results (351-360 of 372) with videos related to

Sort By:
Pageof 38
Cell Reports|August 10, 2023
Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopesRajeshwer S Sankhala, Vincent Dussupt, Gina Donofrio, et al.
The Lancet. Infectious Diseases|January 29, 2022
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre studySaranya Sridhar, Arnel Joaquin, Matthew I Bonaparte, et al.
Plos Pathogens|August 4, 2015
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesSampa Santra, Georgia D Tomaras, Ranjit Warrier, et al.
The New England Journal of Medicine|April 2, 2015
A Recombinant Vesicular Stomatitis Virus Ebola VaccineJason A Regules, John H Beigel, Kristopher M Paolino, et al.
Structure (London, England : 1993)|December 29, 2023
Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domainRajeshwer S Sankhala, Vincent Dussupt, Wei-Hung Chen, et al.
Plos One|November 18, 2017
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120Allan C deCamp, Morgane Rolland, Paul T Edlefsen, et al.
Vaccines|May 28, 2022
A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) ModelSara C Johnston, Keersten M Ricks, Ines Lakhal-Naouar, et al.
JCI Insight|December 13, 2016
Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaquesKan Luo, Hua-Xin Liao, Ruijun Zhang, et al.
Nature Immunology|October 30, 2021
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinationsVincent Dussupt, Rajeshwer S Sankhala, Letzibeth Mendez-Rivera, et al.
Lancet (London, England)|July 27, 2018
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H Barouch, Frank L Tomaka, Frank Wegmann, et al.
Pageof 38